RecruitingPhase 1NCT07737717
Rare condition
Ebola hemorrhagic fever
3
studies recruiting now
as of 7 Sept 2026
129
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
30 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07565090
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
RecruitingPhase 3NCT06126822
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Ebola hemorrhagic fever studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Ebola hemorrhagic fever study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Ebola hemorrhagic fever
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
5 approved treatments and 17 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Odesivimab (Odesivimab component of inmazeb -ebgn)Approved: Ansuvimab (Ebanga)Approved: Atoltivimab (Atoltivimab component of inmazeb -ebgn)Approved: Vaccinia Virus, Modified Encoding Ebola Virus Glycoprotein And Nucleoprotein (Mvabea)Approved: Maftivimab (Maftivimab component of inmazeb -ebgn)
Phase 3Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein (Ervebo)
Phase 2/3Larcaviximab (Larcaviximab component of zmap c4g7)
Phase 2/3Porgaviximab (Porgaviximab component of zmap c2g4)
Phase 2/3Cosfroviximab (Cosfroviximab component of mb-003 c13c6-fr1)
Phase 2/3Amiodarone
Phase 2/3Remdesivir (Veklury)
Phase 2Brincidofovir (Tembexa)
Phase 2Favipiravir
+ 9 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).